RISK FACTORS IN BRONCHOPULMONARY DYSPLASIA

描述：一组403名VLBW（<1500 g）新生儿护理幸存者，出生于 在1988年8月至1991年6月期间，一直跟踪到5-8岁。 的时间 出生日期包括表面活性剂治疗的批准日期。 因此，我们认为， 第一个在普通新生儿ICU接受表面活性剂治疗的儿童 （新生儿重症监护室）的做法，现在进入学龄，提供了第一次机会， 评估学校表现，并评估呼吸道疾病的真正慢性化， 局限性。 现有的队列为此类人提供了独特的机会 评估，因为它跨越表面活性剂批准期，是大于其他 美国随访队列，并代表NICU幸存者， 地理区域。 拟议的研究将利用 有机会利用标准化学校成绩测试在第三届 和四年级以及丰富的其他学校记录信息。 最近 经过验证和标准化的便携式峰值流量测量设备将 用于肺部评估，因为队列在地理上分散。 关于该队列的大型NICU和随访数据库包含广泛的 呼吸系统疾病基线评估、新生儿治疗和 诊断以及功能评估、健康状况和保健 4-6岁时使用。 添加10岁以下的数据将确认或 对4-6岁儿童的功能结果可能较低的调查结果存在争议， 在表面活性剂上市后出生的儿童， 长期呼吸道疾病的发病率保持不变。 新 将收集的结果数据包括学校表现， 记录、家长和教师问卷、呼吸功能（按峰值） 按父母列出的流量计和呼吸道症状以及呼吸道药物 访谈和问卷调查。 这些数据将通过以下方式处理：1）VLBW如何 孩子们与来自同一所学校的正常人和对照组进行比较， （二）出生年份之间是否有时间趋势;及（三） 什么因素是预测性的，利用基线，幼儿期， 并发数据

DESCRIPTION: A cohort of 403 VLBW (<1500 g) neonatal care survivors, born during August 1988-June 1991, have been followed to ages 5-8. The time period of birth includes the approval dates for surfactant therapy. Hence, the first children to be treated with surfactant in general neonatal ICU (NICU) practice are now entering school age, providing a first opportunity to evaluate school performance, and to assess true chronicity of respiratory limitations. The existing cohort provides a unique opportunity for such evaluation, as it spans the surfactant approval period, is larger than other U.S. follow-up cohorts, and is representative of NICU survivors in a geographic area. The proposed research will take advantage of the opportunity to tap into standardized school achievement testing in the third and fourth grades and a wealth of other school record information. Recently validated and standardized portable peak flow measurement devices will be utilized for pulmonary assessment as the cohort is geographically dispersed. A large NICU and follow-up data base on the cohort contains extensive baseline assessment of respiratory disease, neonatal treatments and diagnoses, as well as functional assessment, health status and health care utilization at ages 4-6. The addition of data up to age 10 will confirm or dispute findings from ages 4-6 that functional outcome may be lower among children born after surfactant was released for marketing, and that the prevalence of long-term respiratory problems has remained the same. The new outcome data to be collected include school performance, from school records, parent and teacher questionnaires, respiratory function by peak flow meters and respiratory symptoms and respiratory medications by parent interview and questionnaires. These data will be addressed by: 1) how VLBW children compare to norms and to comparison groups from the same schools and districts; 2) whether there has been a time trend across birth years; and 3) what factors are predictive, utilizing baseline, early childhood and concurrent data.